Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | EDNRB | P24530 | 1/20 | 0.47 |
| ▸ | EDNRA | P25101 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3836047 | 0.78 | PTGS2 (0.71) | PTGS2PTGS1 | |
| SCHEMBL8654540 | 0.74 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL7000824 | 0.74 | PTGS2 (0.55) | PTGS2PTGS1CA12CA2CA9 | |
| SCHEMBL6990927 | 0.74 | PTGS2 (0.64) | PTGS2PTGS1EDNRBEDNRA | |
| SCHEMBL10073203 | 0.74 | PTGS2 (0.64) | PTGS2PTGS1CA12CA2CA9 | |
| SCHEMBL6725632 | 0.72 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6997643 | 0.71 | PTGS2 (0.51) | PTGS2PTGS1CA12CA2CA9 | |
| SCHEMBL8383818 | 0.70 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL3822447 | 0.69 | PTGS2 (0.55) | PTGS2PTGS1CA12CA2CA9 | |
| SCHEMBL5723798 | 0.68 | PTGS2 (0.62) | PTGS2PTGS1CA12CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109214-B2 | Substituted cyclopentene compounds | GRUNENTHAL GMBH (DE) | 2006-09-19 | — | — | US | disclosed |
| US-20050272955-A1 | Substituted cyclopentene compounds | GRUNENTHAL GMBH (DE) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272955-A1 | Substituted cyclopentene compounds | SQLE, CYP3A5, CYP2F1 | PTGS2 306/4885PTGS1 141/4885CA12 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.